Craig joined USVP as an EIR in November, 2012. Craig has been involved in the science and business of the biotechnology industry for more than 25 years. He has been an executive at successful, innovative companies in the biotechnology industry ranging from start-ups to multi-billion dollar public companies. While his specific responsibilities have included business development, finance, portfolio analysis and strategic planning, his passion is the transition of fundamental scientific breakthroughs from the laboratory to drug discovery and development.
Craig came to USVP following the sale of Human Genome Sciences to Glaxo SmithKline where he was Senior Vice President, Strategy and Corporate Development. Before HGS, Craig was co-founder of Vega Therapeutics, a drug discovery stage biotechnology start-up in the emerging field of inflammation, insulin resistance and energy balance. Before founding Vega Therapeutics, Craig was Senior Vice President of Corporate Development and Finance at Proteolix, a clinical development stage biotechnology company developing novel oncology drug candidates. Proteolix was sold to Onyx Pharmaceuticals in 2009. Craig’s operating experience in the biotechnology industry includes his time as Senior Vice President at Immunex Corporation where he was General Manager of the Specialty Therapeutics franchise. In that capacity, he managed a business unit with more than $200 million in product sales that discovered, developed, manufactured and marketed oncology and neurology products. While at Immunex, Craig led a number of important business development alliances and had leadership roles on several Joint Clinical Development Steering Committees. His earlier career included senior executive positions in finance, biotechnology equity research and venture capital at Lehman Brothers, Credit Suisse, Donaldson, Lufkin and Jenrette, and J.P. Morgan & Co.
Craig currently serves on the Science Advisory Board of the Life Sciences Institute at the University of Michigan and Chairs the Institute’s Leadership Council. He is also on the scientific evaluation board for the LSI’s Innovation Partnership Fund. He has been a guest lecturer at the Haas School of Business at UC Berkeley, the Stephen M. Ross School of Business at the University of Michigan and the Schools of Medicine and Engineering at the University of Michigan. Craig received his undergraduate degree in Biological Sciences from the University of Chicago, an MBA from the University of Michigan Stephen M. Ross School of Business, and attended the Georgetown University School of Medicine.